Highlights enVVeno Medical Corporation

Equities

NVNO

US29415J1060

Delayed Nasdaq Other stock markets 03:43:57 2024-04-29 pm EDT			5-day change	1st Jan Change
5.17 ^USD	-0.19%		+5.30%	+0.58%

Apr. 16	EnVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024	CI
Apr. 09	EnVVeno Medical Corporation Appoints Andrew Cormack as Its Chief Commercial Officer	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EnVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024	Apr. 16	CI
EnVVeno Announces Positive Topline Efficacy Data for VenoValve US Pivotal Trial	Mar. 06	MT
EnVVeno Medical Corporation Announces the Presentation of Positive Topline Efficacy Data Showing Significant Clinical Improvement from the Savve U.S. Pivotal Trial for the Venovalve	Mar. 06	CI
EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
EnVVeno Medical Corporation Presents Positive Preliminary Device Related Material Adverse Event Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium	Nov. 16	CI
EnVVeno Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
EnVVeno Medical Corporation Achieves Full Enrollment for VenoValve U.S. Pivotal Trial	23-10-06	CI
EnVVeno Medical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-31	CI
Envveno Medical Corporation Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study	23-07-05	CI
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-02	CI
Envveno Medical Corporation Presents Positive Long-Term, Three-Year Observational Data from A Cohort of Patients That Participated in the Previously Concluded Venovalve First-In-Human Clinical Tria	22-11-17	CI
EnVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study	22-11-07	CI
EnVVeno Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-27	CI
EnVVeno Medical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-03	CI
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
EnVVeno Medical Secures US Patent for Manufacturing Method Related to VenoValve	22-04-11	MT
EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-28	CI
EnVVeno Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
EnVVeno Medical : Says First VenoValve Surgery Completed in Study	21-10-22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights enVVeno Medical Corporation

Equities

NVNO

US29415J1060

Highlights

Filters